Daily Anesthesiology Research Analysis
Analyzed 127 papers and selected 3 impactful papers.
Summary
Three impactful anesthesiology/critical-care studies stood out: a multicenter RCT found that albumin supplementation did not improve 90-day mortality in septic shock; a multicenter randomized trial showed McGrath videolaryngoscopy did not outperform direct laryngoscopy for rapid sequence intubation; and a large individual patient data analysis linked higher driving pressure to mortality in ARDS, especially in pulmonary ARDS. Collectively, these results refine fluid therapy choices, airway device selection during RSI, and ventilator targets.
Research Themes
- Airway management and device effectiveness during rapid sequence intubation
- Fluid resuscitation strategy in septic shock
- Ventilator settings and driving pressure in ARDS
Selected Articles
1. McGrath videolaryngoscopy versus direct laryngoscopy for rapid sequence intubation: A multicenter randomized clinical trial.
In a multicenter randomized trial of 400 RSI patients, McGrath videolaryngoscopy did not improve glottic view or first-pass success versus direct laryngoscopy, and modestly prolonged intubation time. Adverse events were rare and similar across groups.
Impact: This directly informs device selection during RSI, challenging assumptions that videolaryngoscopy universally improves performance in routine elective RSI settings.
Clinical Implications: For routine elective RSI, direct laryngoscopy remains a viable first-line approach; McGrath VL may be reserved for anticipated or encountered difficulty rather than routine use.
Key Findings
- No significant difference in Grade 1 modified Cormack-Lehane view (46.6% VL vs 42.3% DL; OR 1.24, 95% CI 0.85-1.79)
- Similar first-attempt intubation success (86.5% VL vs 87.6% DL; P=0.76)
- Longer median time to intubation with VL (35 s) than DL (30 s; HR 1.27, 95% CI 1.04-1.56)
Methodological Strengths
- Multicenter, randomized, patient-blinded design
- Clinically relevant outcomes (first-pass success, intubation time) with prespecified analyses
Limitations
- Elective surgical population may limit generalizability to emergency/ICU RSI
- Operators’ experience and adjunct use were not detailed, which may influence performance
Future Directions: Evaluate device performance in higher-risk RSI (e.g., emergency/ICU, predicted difficult airways), standardize adjuncts, and assess training effects.
BACKGROUND: Videolaryngoscopy has been proposed to improve glottic visualization and intubation success during rapid sequence intubation (RSI). Evidence on the effectiveness of the McGrath videolaryngoscope in this setting remains limited. METHODS: In this multicenter, patient-blinded, randomized trial, 400 adults undergoing elective non-cardiac surgery requiring RSI were assigned to McGrath videolaryngoscopy (VL, n = 193) or direct laryngoscopy (DL, n = 201). The primary outcome was glottic visualization using the modified Cormack-Lehane (CL) classification. Secondary outcomes included first-attempt intubation success, number of attempts, intubation failure, and time to intubation. Safety outcomes included airway injury and postoperative complications. RESULTS: Glottic visualization did not differ significantly between groups (Grade 1 view: VL 46.6% vs DL 42.3%; OR 1.24, 95% CI 0.85-1.79; P = 0.26). First-attempt success was similar (VL 86.5% vs DL 87.6%; P = 0.76). Intubation failure occurred in 1.6% of VL and 0.5% of DL cases (P = 0.29). Median time to intubation was longer with VL (35 s vs 30 s; HR 1.27; 95% CI 1.04-1.56; P = 0.016). Rates of airway trauma and postoperative complications were low and comparable. CONCLUSIONS: In adult patients undergoing RSI, McGrath videolaryngoscopy did not improve glottic visualization or first-pass intubation success compared with direct laryngoscopy, and was associated with a modestly longer intubation time. Adverse events were infrequent and similar. These findings suggest that the routine use of McGrath for RSI may not confer clinical benefit in low-risk elective surgical populations.
2. Albumin Replacement Therapy in Septic Shock: A Randomized Clinical Trial.
Among 440 patients with septic shock randomized to albumin-based versus crystalloid fluid strategies, 90-day mortality did not differ (43.3% vs 45.9%; RR 0.94; P=0.71), and no secondary endpoints favored albumin. Early termination limits precision, but findings suggest no survival benefit.
Impact: Provides high-quality randomized evidence addressing a common fluid choice in septic shock, supporting crystalloid-first strategies and reducing low-value albumin use.
Clinical Implications: Crystalloids should remain the default resuscitation fluid in septic shock; albumin may be reserved for select indications rather than routine mortality benefit.
Key Findings
- No reduction in 90-day mortality with albumin vs. standard fluids (43.3% vs 45.9%; RR 0.94; 95% CI 0.76–1.17; P=0.71)
- No significant differences in secondary outcomes, including ICU/hospital mortality and organ failure
- Albumin strategy was safe but the trial ended early due to low enrollment
Methodological Strengths
- Multicenter randomized design with standardized albumin target protocol
- Clinically meaningful primary endpoint (90-day mortality)
Limitations
- Open-label design and premature termination reduce power and may introduce bias
- Conducted in Germany; external generalizability may vary
Future Directions: Further adequately powered RCTs or meta-analyses should assess subgroups (e.g., hypoalbuminemia, fluid-positive balance) and patient-centered outcomes.
IMPORTANCE: Albumin supplementation may reduce mortality in patients with septic shock; however, data from randomized clinical trials are limited. OBJECTIVE: To assess the impact of albumin administration on outcomes in patients with septic shock. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label randomized clinical trial was conducted between October 21, 2019, and May 2, 2022. Patients from 23 intensive care units in Germany enrolled within 24 hours of the onset of septic shock were followed up for outcome data up to 90 days. The statistical trial report was completed and filed with the federal authorities in December 2023; additional analyses were completed in October 2024. The study was terminated prematurely due to low enrollment rates. INTERVENTIONS: Protocol group patients received 20% albumin to maintain serum albumin levels of at least 3.0 g/dL for up to 28 days during their intensive care unit admission. The control group received standard fluid administration with crystalloids. MAIN OUTCOMES AND MEASURES: The primary end point was 90-day mortality; secondary end points included 28-day, 60-day, intensive care unit and in-hospital mortality, organ dysfunction or failure, total amount of fluid administration and total fluid balance while in the intensive care unit, duration of intensive care and hospital stays, and frequency of adverse events. RESULTS: Of 440 randomized patients (median [IQR] age, 69 [59-78] years; 290 [65.9%] male), 222 received albumin and 218 received standard fluids. Baseline characteristics were comparable. Ninety-day mortality was 43.3% (91 of 210) in the albumin group vs 45.9% (96 of 209) in controls (relative risk, 0.94; 95% CI, 0.76-1.17; P = .71). No significant differences were observed for secondary end points. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of patients with septic shock, albumin administration was safe but did not improve 90-day survival. As this trial was prematurely terminated, results remain inconclusive and additional studies are recommended. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03869385.
3. Potentially modifiable ventilatory factors contributing to outcome in patients with pulmonary and extrapulmonary ARDS - An individual patient data analysis.
Across 7,934 ARDS patients from six studies, higher driving pressure and respiratory rate associated with 60-day mortality; the association of driving pressure was stronger in pulmonary ARDS, while tidal volume showed no association. In sensitivity analyses excluding COVID-19, only driving pressure remained associated.
Impact: Refines ventilator strategy by identifying driving pressure as a key modifiable target, particularly in pulmonary ARDS, informing personalized lung-protective ventilation.
Clinical Implications: Prioritize minimizing driving pressure (ΔP) as a central ventilatory target, with attention to etiology (pulmonary vs extrapulmonary) when titrating settings; tidal volume alone may be insufficient as a mortality surrogate.
Key Findings
- Among 7,934 ARDS patients, 60-day mortality was 43%
- Higher driving pressure (ΔP) and respiratory rate (RR) associated with increased 60-day mortality
- ΔP had stronger association in pulmonary ARDS (interaction p<0.001); tidal volume was not associated with mortality
Methodological Strengths
- Large individual patient data pooled analysis across six studies
- Etiology-specific interaction testing (pulmonary vs extrapulmonary ARDS) with sensitivity analyses
Limitations
- Observational source studies limit causal inference
- Heterogeneity in ventilation protocols across contributing studies
Future Directions: Prospective trials targeting driving pressure reduction stratified by ARDS etiology; mechanistic work to explain etiology-specific vulnerability.
BACKGROUND: Previous studies have identified potentially modifiable factors associated with mortality from acute respiratory stress syndrome (ARDS), however these studies did not differentiate between underlying causes of ARDS. As the etiology of ARDS may influence patient outcomes, we aimed to identify potentially modifiable factors associated with 60-day mortality from pulmonary and extrapulmonary ARDS. METHODS: Secondary pooled analysis of six observational studies studies on mechanical ventilation in patients with pulmonary and extrapulmonary ARDS. The primary endpoint was mortality at day 60 after inclusion. Exploratory outcomes included length of stay in hospital and ICU, duration of ventilation and ventilator-free days at day 28. RESULTS: Out of 7934 patients with pulmonary or extrapulmonary ARDS, 3402 (43%) did not survive. Potentially modifiable factors associated with 60-day mortality included high driving pressure (ΔP) and high respiratory rate (RR). There was an interaction between etiology of ARDS and ΔP on 60-day mortality, with ΔP showing a stronger association in pulmonary ARDS compared with extrapulmonary ARDS (p < 0.001). In a sensitivity analysis excluding COVID-19 patients, RR was no longer associated with 60-day mortality, whereas ΔP remained associated. Tidal volume was not associated with 60-day mortality in either pulmonary or extrapulmonary ARDS. No interaction was found between ARDS etiology and RR or tidal volume on 60-day mortality. CONCLUSION: High ΔP and high RR were associated with 60-day mortality in patients with pulmonary and extrapulmonary ARDS receiving mechanical ventilation, with ΔP showing a stronger association in pulmonary ARDS compared with extrapulmonary ARDS. REGISTRATION: The pooled database was registered at ClinicalTrials.gov (identifier NCT05650957).